US Edition
News from ALS News Today
We’ve assigned a rating of Unknown factuality to ALS News Today. You can read more about how we’ve determined ALS News Today’s credibility and reliability as a news source here: https://ground.news/rating-system.
Media Bias Ratings
Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top ALS News Today News
Alzheimer's DiseaseThe results of the MIROCALS randomized clinical trial have shown that adding low-dose interleukin-2 (IL2LD) to standard treatment for amyotrophic lateral sclerosis slowed functional decline and extended the lifespan of people with this degenerative disorder.See the Story
Low-dose interleukin-2 added to standard ALS treatment extends patient survival, clinical trial finds
100% Center coverage: 2 sources
CancerEli Lilly is licensing rights to a Phase 1-ready antibody that startup Alchemab developed for amyotrophic lateral sclerosis and other neurodegenerative disorders. Lilly’s pipeline has ALS drug candidates from previous deals with QurAlis and Verge Genomics. The post Eli Lilly Turns to Alchemab to Add Another AI-Discovered ALS Drug Prospect appeared first on MedCity News.See the Story
Eli Lilly Turns to Alchemab to Add Another AI-Discovered ALS Drug Prospect
100% Center coverage: 2 sources
